VEGFA and non-small cell lung carcinoma: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has been used to boost the chemotherapy efficacy in patients with non-squamous NSCLC (NS-NSCLC) [6,7].